key: cord-1054795-hlh8hst7
authors: Hsu, Caroline M.; Lacson, Eduardo K.; Manley, Harold J.; Aweh, Gideon N.; Miskulin, Dana; Johnson, Doug; Weiner, Daniel E.
title: Seroresponse to Third Doses of SARS-CoV-2 Vaccine Among Patients Receiving Maintenance Dialysis
date: 2022-04-01
journal: Am J Kidney Dis
DOI: 10.1053/j.ajkd.2022.03.002
sha: 46bc06b46a811f47a3c6a3044bf7682f236aad60
doc_id: 1054795
cord_uid: hlh8hst7

nan

Beginning August 13, 2021, third doses of SARS-CoV-2 mRNA vaccine were recommended for patients with immunocompromise, 1 possibly but not definitively including patients undergoing dialysis, 2 who have increased risk for poor outcomes from COVID-19. 3 In this study, we examined the seroresponse to an additional dose of vaccine in this vulnerable population.

Dialysis Clinic, Inc. (DCI) is a national not-for-profit provider caring for approximately 15,000 patients at 260 outpatient dialysis clinics in 29 states. As previously described, beginning in January 2021, DCI physicians had the option of activating a SARS-CoV-2 vaccine protocol, in which anti-spike immunoglobulin G (anti-spike IgG) antibodies were drawn monthly with routine labwork. 4 The chemiluminescent assay ADVIA Centaur® XP/XPT COV2G had received emergency use authorization (EUA) in July 2020 and measures anti-spike IgG antibodies against the receptor-binding domain of the S1 subunit of SARS-CoV-2 spike antigen. 5 This semi-quantitative assay reports an Index Value between 0 and ≥20 established with calibrators; per manufacturer specifications, anti-spike IgG titer ≥1 Index represents detectable antibodies, likely signifying seroresponse. 5 This study includes all adult patients who received an additional SARS-CoV-2 vaccine dose after completion of an initial series, and who had at least one anti-spike IgG level checked both between the initial series and the additional dose, and at least 14 days after the additional dose. Among patients who developed COVID-19 at any time after completing an initial series, titer levels measured after development of COVID-19 were excluded from analysis. Demographic and clinical data, vaccination dates, history of COVID-19 diagnosis, and anti-spike IgG titer results were obtained from the DCI electronic health record.

For each patient, three titer levels of interest were identified: (1) the maximum level reached at least 14 days after completion of the initial vaccine regimen but before the additional vaccine dose (labeled "Max Pre-"); (2) the last titer measured prior to the additional vaccine dose ("Last Pre-"); and (3) the first titer measured after the additional vaccine dose ("First Post-"). In analyses, strata of ≥20, 7-<20, and <7 J o u r n a l P r e -p r o o f Index were used. The threshold of 20 reflects the semi-quantitative nature of the assay used, while the threshold of 7 represents a hypothesized level of protection from severe disease. 6 This study was approved for exemption by the WCG IRB Work Order 1-1456342-1. Statistical analyses were performed using R v4.0.2.

A total of 399 patients had received an additional vaccine dose. Only four patients received Ad26.COV2.S/Janssen as the initial vaccine regimen and were therefore excluded from further analysis ( Figure S1 ). Of the remaining 395 patients, 294 (74%) received a homologous vaccine regimen ( Figure   S2 ). No patient received a reduced ("booster") dose of mRNA-1273/Moderna vaccine. Baseline characteristics are shown in Table S1 .

Among the 395 third dose recipients, 336 (85%) had maximal antibody response ≥7 after the initial series ("Max Pre-"), and 203 (51%) had titer ≥7 just prior to the third dose ("Last Pre-"), measured median 16 [IQR 12-28] days before the third dose (Table 1A) . Following administration of the third dose, 383 (97%) patients had seroresponse ≥7, measured median 33 [IQR 21-40] days later. Among the 59 patients whose maximal response after the initial regimen was <7, 49 (83%) had titer ≥7 following the third dose. Among the 192 patients whose titer had waned to <7 prior to the third dose, 180 (94%) had titer ≥7 following the third dose. Analyses were repeated for subgroups by COVID-19 history (Tables 1B-C) and by vaccine type (Table S2) ; results were not notably different, though numbers were limited for patients with COVID-19 history. Analyses with an additional stratum of <1 Index are shown in Table S3 .

Among maintenance dialysis patients, a third dose of mRNA SARS-CoV-2 vaccine is associated with a high prevalence of seroresponse. Previous studies have shown that, while patients receiving maintenance dialysis are able to mount a robust initial immune response, this seroresponse wanes over time. 7 Studies of the BNT162b2/Pfizer vaccine in France showed that a third dose administered shortly after a second dose was associated with increased seroresponse. [8] [9] [10] [11] [12] The current study includes a larger cohort with representation of both mRNA-1273/Moderna and BNT162b2/Pfizer recipients. The data J o u r n a l P r e -p r o o f further demonstrate robust seroresponse with titers ≥7 in 97% of recipients of a third vaccine dose, including 94% of those whose response to an initial mRNA vaccine regimen had waned to <7.

Given ongoing high rates of COVID-19 and rapidly waning immunity after an initial vaccine series, additional or booster doses of SARS-CoV-2 vaccine provided to all maintenance dialysis patients likely will have substantial benefits. Adequate seroimmunity is thought to both reduce breakthrough infections and hospitalizations, and reduce transmission by those who have the infection; [13] [14] [15] all are crucial for patients receiving maintenance dialysis, who are at increased risk for poor outcomes.

Nevertheless, a non-negligible proportion of patients still have low titers even after a third dose and may benefit from a fourth ("booster") dose, as has been given to kidney transplant recipients with poor seroresponse, 16 or from prescription of tixagevimab plus cilgavimab (Evusheld) prophylaxis. 17 Of note, a test-based approach to re-dosing of vaccine is already used for hepatitis B vaccination among patients receiving dialysis. 18 This study has limitations, including lack of data on cellular immunity and possible selection bias, both in the enrollment for antibody monitoring and for the administration of additional vaccine dose. We did not correlate antibody levels to breakthrough infections. Durability of seroresponse to the third dose remains unknown. The assay used is semi-quantitative and has EUA but not full approval. Importantly, a major strength is that this study includes real-world results on seroresponse to additional doses of SARS-CoV-2 vaccination.

In conclusion, additional SARS-CoV-2 vaccine doses elicit robust seroresponse among patients receiving maintenance dialysis, including among patients whose seroresponse has lapsed, suggesting that additional vaccine doses may play a role in maximizing and sustaining protection of maintenance dialysis patients.

Authors' Contributions: Research area and study design: CMH, EKL, HJM, DM, DEW; data acquisition: GNA; data analysis and interpretation: CMH, EKL, HJM, GNA, DM, DEW; statistical analysis: CMH; supervision or mentorship: EKL, DJ, DEW. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate. Support: This report was supported by Dialysis Clinic, Inc. CMH receives support from ASN KidneyCure's Ben J. Lipps Research fellowship. CMH's funder had no role in study design, data collection, reporting, or the decision to submit. Green cells indicate increase in stratum from pre-third dose to post-third dose. Baseline was defined as anti-spike IgG titer > 1 Index before or within 10 days after first dose of vaccine (representing likely prior COVID-19 which may or may not have been diagnosed). Prior COVID-19 was defined as positive SARS-CoV-2 test before full immunity (at 14 days after completion of initial vaccine series). 

Signing the Advisory Committee on Immunization Practices' Recommendation for an Additional Dose of an MRNA COVID-19 Vaccine in Moderately to Severely Immunocompromised People

Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms

COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider

Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients

SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections in Maintenance Dialysis Patients. medRxiv

Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months

High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis

Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis

SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis

COVID-19 vaccination in haemodialysis patients: good things come in threes…

Evidence for antibody as a protective correlate for COVID-19 vaccines

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

Evusheld) for Pre-Exposure Prophylaxis of COVID-19

Guidelines for Vaccinating Kidney Dialysis Patients and Patients with Chronic Kidney Disease